Medical Stock Performance Analysis
Delivered September 1, 2020. Contributor: Alexandra I.
Goals
To inform equity investment decisions in the telehealth space by identifying ten of the leading publicly traded, pure-play telehealth companies, including their name, a brief description of their business, their stock performance history since the start of the pandemic and links to relevant analyst commentary. Ideally, data will be provided within a spreadsheet.
Early Findings
Publicly Traded, Pure-Play Telehealth Companies
- The first hour of research suggests that there are no leading, publicly traded, pure-play telehealth companies apart from Teladoc.
- The research team first identified leading pure-play telehealth companies based on the expert opinion of MarketsandMarkets, IBISWorld and Fortune Business Insights, which identified a cohort of companies that are currently the "key market players" and "biggest companies" in telehealth globally.
- Notably, all of the top telehealth companies appear to be either diversified organizations or privately held companies (e.g., Doctor on Demand, MDLive, Medvivo Group, Zipnosis, Dictum Health, Amwell, Grand Rounds, HelloMD).
Publicly Traded, Pure-Play Digital Therapeutics Companies
- As a separate strategy for identifying publicly traded investment opportunities in the medical industry during the pandemic, the research team looked into the digital therapeutics market.
- Notably, the digital therapeutics industry is expected to expand significantly amid the coronavirus outbreak, due to additional consumer adoption of digital therapeutics services as well as the improving regulatory environment.
- Moreover, initial research suggests that Livongo and Health Catalyst are two leading, pure-play digital therapeutics companies that can be publicly traded through equity markets.
Research proposal:
Only the project owner can select the next research path.